Ask AI
Improving Outcomes in Pediatric Patients with AD

CE / CME

From Flare to Control in Atopic Dermatitis: Improving Outcomes in Pediatric Patients With Moderate to Severe Disease

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: June 27, 2025

Expiration: June 26, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Katie Smiley, PA-C, and Joy Wan, MD, discuss how AD presents differently in pediatric patients, what treatment options are available to them, and the importance of using SDM and developing an AD action plan to optimize outcomes.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be downloaded here or by clicking any of the slide thumbnails in the module alongside the expert commentary. 

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning and once at the end of the activity. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

A 7-year-old girl presents with moderate to severe atopic dermatitis (AD) that has been poorly controlled with emollients and low-potency topical corticosteroids. She has significant pruritus, sleep disturbance, and frequent flares, which have affected her school performance and emotional well-being. Her parents report feeling overwhelmed by the time-consuming treatment regimen. Which of the following would be the most appropriate next step in managing this patient’s AD?

A 10-yr-old boy with moderate to severe AD has experienced inadequate symptom control with high-potency topical corticosteroids and topical calcineurin inhibitors. He continues to have significant pruritus, sleep disruption, and poor quality of life. You are considering starting a biologic therapy. Based on the current evidence, which of the following biologic therapies is the most appropriate for this patient?

A 9-year-old girl with moderate to severe AD presents with persistent pruritus, skin lesions, and difficulty sleeping despite using topical corticosteroids and emollients. You are considering initiating a systemic biologic therapy. To incorporate shared decision-making (SDM) into the treatment plan, which of the following would be the most effective approach?

How confident are you in treating your pediatric patients with atopic dermatitis?

How many people with AD do you provide care for in a typical week?

Which best describes your practice setting?